STOCKWATCH

Lupin Ltd. Subsidiary Appoints Mr. Claus Jepsen as President, Global Specialty

Lupin Ltd.'s wholly owned subsidiary, Lupin Management, Inc., USA, has appointed Mr. Claus Jepsen as ‘President, Global Specialty’ with over 30 years of experience in the pharmaceutical industry. Mr. Jepsen has led commercial strategy, portfolio choices, and launch planning across Europe, Asia, and the United States. He has worked with Takeda Pharmaceuticals, GSK, and launched major brands like Ellipta in the U.S. His role will accelerate Lupin’s plans to evolve its specialty brand business and to achieve its mission to bring access to innovative medicines for patients and communities it serves.

• Lupin Management, Inc., USA has appointed Mr. Claus Jepsen as ‘President, Global Specialty’.
• Mr. Jepsen has over 30 years of experience in the pharmaceutical industry.
• He has led commercial strategy, portfolio choices, and launch planning across Europe, Asia, and the United States.
• Mr. Jepsen has worked with Takeda Pharmaceuticals and GSK, launching major brands like Ellipta in the U.S.
• His role will help Lupin to evolve its specialty brand business and bring access to innovative medicines for patients and communities it serves.